



Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Hiroyuki Okuzawa, Representative Director,
President and COO

(Code no.: 4568, Prime Market, Tokyo Stock Exchange)

Please address inquiries to Kentaro Asakura,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<https://www.daiichisankyo.com>

Arbitrator Issues Final Award, Ordering Seagen to Pay Daiichi Sankyo Arbitration Costs and Attorneys' Fees Following Ruling in Favor of Daiichi Sankyo in Dispute with Seagen

Tokyo and Basking Ridge, NJ – (November 20, 2023) – An arbitrator in a dispute between Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) and Seagen Inc. (“Seagen”) regarding Daiichi Sankyo’s antibody drug conjugate technology issued a final decision requiring Seagen to pay approximately \$45.5 million in attorneys’ fees and arbitration costs to Daiichi Sankyo.

The final award follows and incorporates the August 12, 2022 decision by the arbitrator denying all claims made by Seagen that it has ownership interest in certain intellectual property rights related to Daiichi Sankyo’s antibody drug conjugate technology.

Any impact on Daiichi Sankyo’s consolidated financials for fiscal year ending March 31, 2024, is currently being evaluated and will be announced at an appropriate time in the future.

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.